Role of bile acids in inflammatory bowel disease

Tiratterra, Elisa; Franco, Placido; Porru, Emanuele; Κατσάνος, Κωνσταντίνος; Christodoulou, Dimitrios; Roda, Giulia

doi:10.20524/aog.2018.0239

Cited by 61 publications

(61 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, production of ansamycins, a family of bacterial secondary metabolites that act as antimicrobial compounds targeting Gram-positive and Gram-negative bacteria, as well as bacteriophages and some poxviruses, 28 would likely have a substantial effect on gut microbial composition. There is conflicting evidence regarding the role of bile acids in UC; 29 however, our findings suggest a beneficial role of conversion to secondary bile acids, specifically, the production of dehydrolithocholate.…”

Section: Discussioncontrasting

confidence: 55%

Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

et al. 2019

View full text Add to dashboard Cite

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative colitis (UC). In a randomized controlled trial of FMT in patients with active UC, we aimed to identify bacterial taxonomic and functional factors associated with response to therapy. METHODS:We performed a double-blind trial of 81 patients with active UC randomly assigned to groups that received an initial colonoscopic infusion and then intensive multidonor FMT or placebo enemas, 5 d/wk for 8 weeks. Patients in the FMT group received blended homogenized stool from 3-7 unrelated donors. Patients in the placebo group were eligible to receive open-label FMT after the double-blind study period. We collected 314 fecal samples from the patients at screening, every 4 weeks during treatment, and 8 weeks after the blinded or open-label FMT therapy. We also collected 160 large-bowel biopsy samples from the patients at study entry, at completion of 8 weeks of blinded therapy, and at the end of open-label FMT, if applicable. We analyzed 105 fecal samples from the 14 individual donors (n ¼ 55), who in turn contributed to 21 multidonor batches (n ¼ 50). Bacteria in colonic and fecal samples were analyzed by both 16S ribosomal RNA gene and transcript amplicon sequencing; 285 fecal samples were analyzed by shotgun metagenomics, and 60 fecal samples were analyzed for metabolome features. RESULTS: FMT increased microbial diversity and altered composition, based on analyses of colon and fecal samples collected before vs after FMT. Diversity was greater in fecal and colon samples collected before and after FMT treatment from patients who achieved remission compared with patients who did not. Patients in remission after FMT had enrichment of Eubacterium hallii and Roseburia inulivorans compared with patients who did not achieve remission after FMT and had increased levels of short-chain fatty acid biosynthesis and secondary bile acids. Patients who did not achieve remission had enrichment of Fusobacterium gonidiaformans, Sutterella wadsworthensis, and Escherichia species and increased levels of heme and lipopolysaccharide biosynthesis. Gastroenterology 2019;156:1440-1454 BASIC AND TRANSLATIONAL ATBacteroides in donor stool were associated with remission in patients receiving FMT, and Streptococcus species in donor stool was associated with no response to FMT. CONCLUSIONS:In an analysis of fecal and colonic mucosa samples from patients receiving FMT for active UC and stool samples from donors, we associated specific bacteria and metabolic pathways with induction of remission. These findings may be of value in the design of microbe-based therapies for UC. ClinicalTrials.gov, Number NCT01896635

show abstract

Section: Discussioncontrasting

confidence: 55%

Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although Klebsiella itself does not produce these compounds, some pathogens (including Klebsiella) are known to be resistant to bile acids [37]. Excessive production of some bile acids and bile acid malabsorption can lead to overabundance of bile acids, which is a hallmark of IBD [38], although the exact mechanisms remain unknown. The ability of Klebsiella to thrive in concentrated bile acid environments is consistent with the high co-occurrence probabilities shown in Figure 6b.…”

Section: E Microbe-metabolite Interactions In Inflammatory Bowel Dismentioning

confidence: 99%

Learning representations of microbe–metabolite interactions

et al. 2019

View full text Add to dashboard Cite

Integrating multi-omics datasets is critical for microbiome research, but multiple statistical challenges can confound traditional correlation techniques. We solve this problem by using neural networks to estimate the conditional probability that each molecule is present given the presence of each specific microbe. We show with known environmental (desert biological soil crust wetting) and clinical (cystic fibrosis lung) examples, our ability to recover microbe-metabolite relationships, and demonstrate how the method can discover relationships between microbially-produced metabolites and inflammatory bowel disease.

show abstract

“…Porphyrin pigments and bile salts are continuously produced in the human body and interact with the gut microbiome and epithelial cells which produce LL-37. Similarly to the peptide, bile salts are also associated with the pathogenesis of various gastrointestinal disorders, such as inflammatory bowel diseases and colorectal cancer [28][29][30]. Furthermore, dietary heme-induced damage and consequent hyperproliferation of the colonic epithelial surface cells have been demonstrated emphasizing the synergistic role of the gut microbiota by reducing the mucus barrier function [31].…”

Section: Accepted Manuscriptmentioning

confidence: 99%